NovaBridge Reports 79% Response Rate for Givastomig in Phase 1b Trial
NovaBridge reported a 79% response rate at the selected dose of givastomig in a Phase 1b trial.
Related stories
Microsoft says outage issue addressed and remaining service restored
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
M impact | EQUITY | Nov 14, 2026, 06:37 AM UTC
Microsoft Completes Outage Fix, Restores Service to Remaining Customers
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
L impact | EQUITY | Nov 14, 2026, 06:37 AM UTC
Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing
Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company
M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC
Microsoft Says Consumer Products Services Recovered
Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery.
M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC
Microsoft restores consumer product services after outage
Microsoft said its consumer product services have been restored; other services are not included in the update.
M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC
Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption
Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider.
M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC